File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/s41401-021-00757-7
- Scopus: eid_2-s2.0-85113779341
- PMID: 34426644
- WOS: WOS:000687548800001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling
Title | Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling |
---|---|
Authors | |
Keywords | breast cancer FAK/Src/Rac1 pathway ITGα3 ITGβ5 metastasis osthole Wenshen Zhuanggu Formula |
Issue Date | 2022 |
Citation | Acta Pharmacologica Sinica, 2022, v. 43, n. 6, p. 1544-1555 How to Cite? |
Abstract | Metastasis is the leading cause of death in breast cancer patients. Osthole, as an active compound detected in the traditional Chinese medicine Wenshen Zhuanggu Formula, has shown a promising anti-metastatic activity in human breast cancer cells, but the underlying mechanisms remain ambiguous. In this study we elucidated the anti-metastatic mechanisms of osthole in highly metastatic breast cancer cells and a zebrafish xenograft model. We showed that the expression of integrin α3 (ITGα3) and integrin β5 (ITGβ5) was upregulated in highly metastatic MDA-MB-231, MDA-MB-231BO breast cancer cell lines but was downregulated in poorly metastatic MCF-7 breast cancer cell line, which might be the key targets of osthole’s anti-metastatic action. Furthermore, we showed that knockdown of ITGα3 and ITGβ5 attenuated breast cancer cell migration and invasion possibly via suppression of FAK/Src/Rac1 pathway, whereas overexpression of ITGα3 and ITGβ5 caused the opposite effects. Consistently, osthole significantly inhibited breast cancer metastasis by downregulating ITGα3/ITGβ5 signaling in vitro and in vivo. These results provide new evidence that osthole may be developed as a candidate therapeutic drug for metastatic breast cancer. |
Persistent Identifier | http://hdl.handle.net/10722/335870 |
ISSN | 2023 Impact Factor: 6.9 2023 SCImago Journal Rankings: 1.882 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chen, Yue qiang | - |
dc.contributor.author | Song, Hai yan | - |
dc.contributor.author | Zhou, Zhong yan | - |
dc.contributor.author | Ma, Jiao | - |
dc.contributor.author | Luo, Zhan yang | - |
dc.contributor.author | Zhou, Ying | - |
dc.contributor.author | Wang, Jian yi | - |
dc.contributor.author | Liu, Sheng | - |
dc.contributor.author | Han, Xiang hui | - |
dc.date.accessioned | 2023-12-28T08:49:22Z | - |
dc.date.available | 2023-12-28T08:49:22Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Acta Pharmacologica Sinica, 2022, v. 43, n. 6, p. 1544-1555 | - |
dc.identifier.issn | 1671-4083 | - |
dc.identifier.uri | http://hdl.handle.net/10722/335870 | - |
dc.description.abstract | Metastasis is the leading cause of death in breast cancer patients. Osthole, as an active compound detected in the traditional Chinese medicine Wenshen Zhuanggu Formula, has shown a promising anti-metastatic activity in human breast cancer cells, but the underlying mechanisms remain ambiguous. In this study we elucidated the anti-metastatic mechanisms of osthole in highly metastatic breast cancer cells and a zebrafish xenograft model. We showed that the expression of integrin α3 (ITGα3) and integrin β5 (ITGβ5) was upregulated in highly metastatic MDA-MB-231, MDA-MB-231BO breast cancer cell lines but was downregulated in poorly metastatic MCF-7 breast cancer cell line, which might be the key targets of osthole’s anti-metastatic action. Furthermore, we showed that knockdown of ITGα3 and ITGβ5 attenuated breast cancer cell migration and invasion possibly via suppression of FAK/Src/Rac1 pathway, whereas overexpression of ITGα3 and ITGβ5 caused the opposite effects. Consistently, osthole significantly inhibited breast cancer metastasis by downregulating ITGα3/ITGβ5 signaling in vitro and in vivo. These results provide new evidence that osthole may be developed as a candidate therapeutic drug for metastatic breast cancer. | - |
dc.language | eng | - |
dc.relation.ispartof | Acta Pharmacologica Sinica | - |
dc.subject | breast cancer | - |
dc.subject | FAK/Src/Rac1 pathway | - |
dc.subject | ITGα3 | - |
dc.subject | ITGβ5 | - |
dc.subject | metastasis | - |
dc.subject | osthole | - |
dc.subject | Wenshen Zhuanggu Formula | - |
dc.title | Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1038/s41401-021-00757-7 | - |
dc.identifier.pmid | 34426644 | - |
dc.identifier.scopus | eid_2-s2.0-85113779341 | - |
dc.identifier.volume | 43 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 1544 | - |
dc.identifier.epage | 1555 | - |
dc.identifier.eissn | 1745-7254 | - |
dc.identifier.isi | WOS:000687548800001 | - |